Menu closed
Smiling man seated in chair.

For moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity

Get to know Zepbound

For moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity

Get to know Zepbound

What is Zepbound?

Zepbound is an injectable prescription medicine that may help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound should be used with a reduced-calorie diet and increased physical activity.

  • Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines.
  • It is not known if Zepbound is safe and effective for use in children.

Why Zepbound?

With moderate-to-severe OSA, breathing during sleep may be interrupted over and over, which may disrupt sleep. But for the first time, there is a prescription medicine that may help: Zepbound® (tirzepatide).

Man in a tan button down confidently smiling

Zepbound (10 mg or 15 mg) significantly reduced breathing disruptions during sleep*†

*Along with a reduced-calorie diet and increased physical activity.

In a 52-week study, adults taking Zepbound (10 mg or 15 mg) went from a starting average of 52.9 breathing disruptions per hour during sleep (as defined by AHI) to 27.6 (vs 50.1 events per hour to 44.8 with placebo). In another 52-week study of adults on positive airway pressure (PAP) therapy, those who took Zepbound (10 mg or 15 mg) went from a starting average of 46.1 breathing disruptions per hour during sleep to 16.8 (vs 53.1 events per hour to 47.6 with placebo).

Zepbound was about 5× more effective in reducing breathing disruptions vs placebo*†

People taking Zepbound had 25.3 fewer breathing disruptions each hour of sleep, while those taking placebo only had 5.3 fewer.

*Along with diet and exercise.

After one year, some people who took Zepbound achieved remission or had mild OSA with no symptoms*‡

Remission or mild OSA with no symptoms: <5 breathing disruptions per hour during sleep or 5-14 breathing disruptions per hour during sleep and Epworth Sleepiness Scale (ESS) ≤10.

*Along with diet and exercise.
In a 52-week study of adults, of those taking Zepbound (10 mg or 15 mg) with a starting average of 52.9 breathing disruptions per hour during sleep (as defined by AHI), 42.2% reached an AHI of <5 or an AHI of 5-14 with ratings on the ESS of ≤10 (vs 15.9% with placebo and a starting average of 50.1). In another 52-week study of adults on PAP therapy, of those taking Zepbound (10 mg or 15 mg) with a starting average of 46.1 AHI, 50.2% reached an AHI of <5 or an AHI of 5-14 with ratings on the ESS of ≤10 (vs 14.3% with placebo and a starting average of 53.1).

AHI=apnea-hypopnea index; ESS=Epworth Sleepiness Scale; OSA=obstructive sleep apnea; PAP=positive airway pressure

Additional results:

Zepbound helps improve the effect of OSA on blood-oxygen levels during sleep

When breathing is disrupted during sleep, blood oxygen levels may decrease. With Zepbound (10 mg or 15 mg), the level and the time of reduced blood oxygen while sleeping (called hypoxic burden) improved.§

*Along with diet and exercise.
§In a 52-week study, adults taking Zepbound (10 mg or 15 mg) had a starting average hypoxic burden of 153.6% min/h that was reduced by 95.2% min/h (vs a starting average of 137.8% min/h that was reduced by 25.1% min/h with placebo). In another 52-week study of adults on PAP therapy, those taking Zepbound (10 mg or 15 mg) had a starting average hypoxic burden of 132.2% min/h that was reduced by 103.0% min/hr (vs a starting average of 142.1% min/h that was reduced by 41.7% min/hr with placebo).

People taking Zepbound for OSA also lost significant weight*

People taking Zepbound (10 mg or 15 mg) lost about 50 lbs (20%).||

Individual results may vary.
Zepbound is not for cosmetic weight loss
*Along with diet and exercise
In a 52-week study, adults taking Zepbound (10 mg or 15 mg) had a starting average body weight of 257.2 lbs that was reduced by 17.7% to 212.4 lbs (vs a starting average 248.6 lbs that was reduced by 1.6% to 244.7 lbs with placebo). In another 52-week study of adults on PAP therapy, those taking Zepbound (10 mg or 15 mg) had a starting average body weight of 255.3 lbs that was reduced by 19.6% to 205.4 lbs (vs a starting average 253.7 lbs that was reduced by 2.3% to 247.6 lbs with placebo)

Zepbound discussion with a doctor icon.

Get ready for your next doctor’s appointment

With a little prep, you can make the most of your time with your doctor. That’s the idea behind our Doctor Discussion Guide.

Click the button below, and take a few minutes to consider your responses to this short list of questions.


Man confidently entering a room.

Unlock savings

You could save on Zepbound.

Check your eligibility

SAFETY SUMMARY WITH WARNINGS

Warning:

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

  • Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
  • Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Kidney problems (kidney failure). Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Depression or thoughts of suicide. You should pay attention to changes in your mood, behaviors, feelings or thoughts. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects

The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn’t go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using Zepbound

  • Your healthcare provider should show you how to use Zepbound before you use it for the first time.
  • Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea which could increase your risk of low blood sugar. Talk to your healthcare provider about low blood sugar levels and how to manage them.
  • If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound.

Review these questions with your healthcare provider:

❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?

❑ Do you take diabetes medicines, such as insulin or sulfonylureas?

❑ Do you have a history of diabetic retinopathy?

❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?

❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?

❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. It is not known if Zepbound passes into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

  • Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979).

How to take

  • Read the Instructions for Use that come with Zepbound.
  • Use Zepbound exactly as your healthcare provider says.
  • Use Zepbound with a reduced-calorie diet and increased physical activity.
  • Zepbound is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.
  • Use Zepbound 1 time each week, at any time of the day.
  • Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.
  • If you take too much Zepbound, call your healthcare provider, seek medical advice promptly, or contact a Poison Center expert right away at 1-800-222-1222.

Zepbound injection is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial.

Learn more

Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979).

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.

ZP CON BS 20DEC2024

Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

INDICATIONS

Zepbound® (ZEHP-bownd) is an injectable prescription medicine that may help adults with:

  • obesity, or some adults with overweight who also have weight-related medical problems to lose excess body weight and keep the weight off.
  • moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.

It should be used with a reduced-calorie diet and increased physical activity.

Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.